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Linear growth patterns have been recorded in children for more than 200 years. The first documented longitudinal study was that by Count Philibert Guereau de Montbeillard in 1777 on his son from birth to 18 years.' This was an important landmark in the application of the scientific method to the study of the normal physiological processes of growth. Throughout the intervening years, the measurement of height has been extended to populations of healthy children and those at risk from an underlying pathology.
Normal growth in a healthy population is judged by an increase in height measured at regular intervals either cross-sectionally at a given age or longitudinally in a cohort of individuals throughout their period of growth. Increments of height show a steady, but not necessarily continuous, increase from birth to late adolescence when epiphyseal closure of the long bones occurs. If growth is expressed as a rate of change in height (cmly) and then plotted against chronological age, a growth pattern emerges that is different from a simple height for age profile (Fig. 1) . A decrease in growth velocity is shown from birth until puberty, when an acceleration in height gain is demonstrable with a peak velocity that is earlier in girls than in boys. Cross-sectional and longitudinal studies of growth velocity allow the construction of growth charts and centile limits for normal populations that can be used to assess an individual's growth pattern and, with suitable weighting for mid-parental height, the potential height of that individual.2 Growth during adolescence is not confined to height, but is also shown by an increase in bi-iliac distance, head circumference and hand length, accompanied by a gain of body weight. In addition to these normal y'iysiological changes, there is a major increase in weight of the reproductive organs-testes, prostate, uterus and ovary-during adolescence. Tanner3 and Marshall4 have quantified these and other physical changes that occur through adolescence. These normal data form the basis with which patients with a suspected pathology that affects growth and/or maturation can be compared.
The construction of population norms for growth and maturation has to take into account secular trends. Tanner' quotes striking data for this. Between 1880 and 1950 records from five separate countries show an average increase of 1 . 5 cm in height and 0.5 kg in body weight per decade for children of 5-7 years, and of 2.5 cm in height and 2 kg in weight per decade in adolescence. Other reports have identified the influence of socioeconomic status,' parental heighth and nutrition' on linear growth and underline the multifactorial basis of the growth process.
GROWTH HORMONE
Structure and assay Growth hormone (GH) has been isolated from pituitary glands obtained from several species including the pig,n the COW,^ and man.I0 Highly purified G H preparations from non-primates fail to give a biological response when injected into monkeys or man." Structural studies of GH preparations have identified similarities and differences in the amino acid sequence between different species, for example, bovine and human GH . I 2 Highly purified monomeric human C H (hGH), isoelectric point 4.9, has a molecular weight of 22 kD, and contains 190 amino acids including four cysteine residues at positions 53, 165, 182 and 189. There is a disulphide bridge between cysteine residues 53 and 165 and a second between residues 182 and 189.
Baumann," in an important and comprehensive study, has reviewed the literature on the nature of the forms of hGH secreted by pituitary somatotrophs and the native forms that are demonstrable in plasma. The studies cited by Baumann have clarified how to distinguish hGH variants generated by storage or proteolytic degradation from the natural forms (Table 1) . The studies quoted further highlight the importance of those factors that affect the proportion and detection of immunoassayable h C H variants in the circulation. These are: binding to high and low affinity hGH binding proteins, differences in receptor affinities between the hGH variants, the degree of in vivo proteolysis and non-specific immunoreactivity due to immunoglobulins. It is clear from these reports that the relative proportions of immunoassayable h C H present in plasma will vary according to clearance rates of the hGH variants. Selective plasma enrichment has been noted of the 20 kD hGH variant and of the oligomeric forms.
The assay performance of polyclonal hGH antisera depends upon the quality of the immunogen that is used to raise them. Imprecision of T \HI c I . The nalive forms of hCH secreled by human prluitary somarorrophs and the major forms found in plasma 
assay performance is exacerbated by matrix effects, including the inappropriate use of serum proteins from some animal sources in buffer diluents. Variations in assay precision are also attributable to the instability of radiolabelled hGH tracers and to differences in immunological potency of the hGH standards used as calibrants. Control of these variables and substitution of monoclonal antibodies lead to lower values of immunoassayable hGH than with polyclonal antisera. l4 The difference between polyclonal and monoclonal antisera assay performance can, in part, be explained by the degree of crossreactivity of the hGH variants in serum with different antisera. These observations emphasize the importance of establishing the characteristics of polyclonal antisera raised to growth hormone preparations. Good quality polyclonal antisera of high affinity and specificity will detect approximately 75% of the 22 kD hGH variant in normal serum.
The genetic control of hGH synthesis has been studied by DNA probing techniques. Two genes, hGH-N and hGH-V, have been located on chromosome 17. The hGH-N gene regulates the synthesis of monomeric (22 kD) hGH that is exclusively synthesized in the pituitary somatotrophs. In contrast, the hGH-V gene controls the synthesis of the 20 kD hGH variant which differs by a 13-aminoacid sequence from the 22 kD monomeric form. There is some evidence that the 20 kD variant is glycosylatedI6 and immunoassayable concentrations are high during the later stages of pregnancy. In the non-pregnant state, approximately 10% of RIA detectable hGH is of the 20 kD form when polyclonal antisera are used for detection." On the other hand, one monoclonal antibody failed to detect the 20 kD variant . I 4 The biological significance of the 20 kD species and charge variants of hGH is uncertain, the latter possibly arising during the course of purification.17 Nevertheless, chemically or enzymatically cleaved fragments of hGH have significant biological potency. 18.19
1~i -1 - the characterization, synthesis and verification of its biological potency by stimulating the synthesis and release of hGH from the anterior pituitary.2' Human GH is released in a pulsatile fashion and has a half-life of approximately 10 rnin." The pulsatility of GH release is attributed to pulses of GHRH that are under the stimulatory control of the neuropeptides dopamine, noradrenaline, serotonin and the inhibitory control of somatostatin (GHRIH). The pulses of GH are sleep entrained and their frequency and amplitude increase as puberty intervenes.2' In a recent review,24 increasing evidence is cited that 1GF-I acts vio a feedback mechanism that inhibits the action of GHRH at pituitary level and, in vifro at least, stimulates GHRIH in isolated hypothalamic remnants. These observations add a new dimension to the understanding of the pulsatile release of hGH.
[hutocrine or paracine)

Control of hGH secretion and receptor binding
Receptors for hGH are to be found in many tissues including muscle, but are most abundant in the liver; a major site for the synthesis of IGF-I and IGF-II.25 Interestingly, a specific GH-binding protein has been identified in the serum of manZh and other species including the rabbitz7 and the pig.2s Investigation of its ontogeny in man has suggested that this binding protein arises from hepatic GH receptor turnover and thus its measurement in serum provides a potential indicator of hepatic hGH receptor development and integrity.2y Studies in normal volunteers and patients with the rare syndrome of Laron dwarfism30 in whom receptors for hGH are non-f~n c t i o n a l ,~~ support the case for measuring serum levels of hGH binding protein in patients with unexplained poor growth.
SOMATOMEDINS: INSULIN-LIKE GROWTH FACTORS
Salmon and D a~g h a d a y~~ were the first to question the hypothesis of a direct effect of growth hormone on epiphyseal growth centres. Their experiments showed that epiphyseal growth plates of hypophysectomized rats did not incorporate radiolabelled sulphate into chondroitin when bovine growth hormone was added to isolated viable cartilage cells in vitro. In contrast, serum from hypophysectomized rats that were pretreated with growth hormone enhanced the incorporation of radiolabelled sulphate into cartilage of the hypophysectomized animals. The conclusion drawn from these critical experiments was that growth hormone stimulates the synthesis of a factor (sulphation factor) in serum and it is this that modulates cellular and linear growth.
The term somatomedin(s) (SM) was subsequently proposed.33 Two important growth promoting peptides have been isolated from mammalian serum, SM-C and multiple stimulating activity (MSA). The latter was first characterized from rat hepatocytes. In view of their marked homology with the cy and p regions of proinsulin, the preferred names for SM-C and MSA are insulin-like growth factor one and two (IGF-I, IGF-II), r e~p e c t i v e l y .~~ The i~olation,~' amino acid sequencing3h and synthesis3' of IGF-I and a number of closely-related peptides with growth-promoting properties rapidly followed. Structurally, SM-C and IGF-I are identical but early preparations of SMC, designated SMA, were subsequently shown to have glutamic acid at position 40 as a deamination product of glutamine. To qualify as an insulin-like growth factor certain criteria must be met (Table 2) . Table 3 lists some of the important physico-chemical characteristics of IGF-I and 11. Unlike G H , these two peptides are not species specific except in some nonmammalian species, notably fish.
There is conflicting evidence regarding the relative importance of endocrine versus local tissue (paracrine) mechanisms for IGF pro-d~c t i o n .~~ This question has been reviewed and the autocrine role of the IGFs by synergism with trophic hormones in specific endocrine glands discussed.3y The data reviewed provide convincing evidence that all three mechanisms are operating. Further, one or more of the IGF binding proteins may exert an endocrine effect by modulating the concentration of IGFs at tissue level. The injection of IGF-I into animals leads to an enhanced growth velocity and an increased incorporation of radiolabelled thymidine into DNA but, weight for weight, IGF-I is less potent than hGH.40 A physiological role for IGF-I1 is less well defined. The hypoglycaemic effect of IGF-I1 has, however, been documented in patients who presented with suppressed insulin levels and inappropriately ---proteins could be achieved by shifts in pH, temperature and/or by the addition of heparin. However, none of these manoeuvres yields a quantitative release of IGF-I from binding proteins.
Indeed only 70% is actually measured, albeit precisely, in some assay^.^' The selective precipitation of IGF-binding proteins by ethanol-acetic acid5' and variants of this reagentSJ followed by neutralization of the extract led to assays which can yield quantitative recoveries of IGF-I. Despite careful optimization of these procedures, difficulties in removing some IGF-I binding protein from serum from non-primate species, have been documented5' and reliable estimates of IGF-I in human serum or plasma have not been universally achieved. This is particularly true of attempts t o measure IGF-I concentrations in human pathological sera that have IGF-binding protein profiles that differ from normal. Silbergeld and colleaguesSh conducted a comparative study using two commercially available kits. One kit measured IGF-I directly in EDTA-plasma and the second required a pre-extraction step by reverse phase chromatography. The pre-extraction procedure revealed an 85% concordance in the detection of low IGF-I levels in hGH deficient patients and a 100% rise in IGF-I in 5 h C H deficient patients during growth hormone treatment. Without pre-extraction only 55% of the same patients showed low basal IGF-I levels and only two of the hGH treated patients showed a rise in IGF-I. The authors cite some of the other important factors that contribute to unreliable assay performance. Serum protease activity is increased after 24 h preincubation at room temperature,'2 and this is believed to alter IGF-binding protein affinities and consequently enhance antibody capture of IGF-I. An upward drift in measured values with time in the non-extraction assay was thought to be attributable to this enhanced proteolytic activity. As with G H assays, the universal acceptance of a single reference standard remains an added difficulty and will not be resolved until a recommended bioengineered standard is employed.
There is a lack of good quality monoclonal antibodies to IGF-I, the production of which may obviate rigorous extraction procedures. Kits are available for measuring IGF-IS7 as are specialist commercial services for the assay of IGF-I in dried serum samples on filter papers obtained from patients with suspected hGH deficiency. In the United Kingdom, several Supraregional Assay Sdrvice (SAS) centres offer the measurement of IGFserum.
IGF-binding proteins
A spectrum of low to high molecular weight ICF-I/IGF-II-binding proteins have been identified in tissues and biological fluids including serum,CX-ho CSF,h' amniotic fluidh2 and seminal fluid.h' The variability of the reported molecular weights of these binding proteins reflects the different physicochemical methods employed and the presence in biological fluids of oligomeric forms of IGF-binding proteins. In addition, authors have frequently used their own nomenclature when recording their findings and have not always stated whether the SDS-PAGE analyses were conducted under reducing or non-reducing conditions. Despite these difficulties, there is general agreement that in normal serum three major species of IGF-binding protein can be demonstrated. Current nomenclature favours the use of the abbreviation IGF-BP followed by numerals 1-3.h4 A growth hormone and caloriedependent IGF-MI-binding protein of molecular weight 150kD predominates in serum when measured by gel permeation chromatography at neutral pH." Acid treatment of this protein gives rise to an acid-stable component of molecular mass 50-60 kD (IGF BP-3) and an acid labile species of 80-100 kD.hS Under non-reducing conditions and with the use of specific radiolabelled antibodies to IGF BP-3 as probes, two glycosylated forms with identical core protein (29 kD) of mol. mass 41.5 and 38.5 kD are demonstrable in serum after SDS-PAGE and Western blotting." A second non-glycosylated binding protein (IGF BP-2), 34 kD, identifiable in serum and CSF, is synthesized by rat liver cell lines (BRL-A).h7,'H A third non-glycosylated IGF-binding protein (IGF BP-I), 28-30 kD, is unique. It is hGH independent and serum concentrations during short-term fasting, are inversely proportional to basal insulin and glucose levels. Further, IGF BP-I shows a marked rise in concentration during an acute phase of restricted calorie intake. A significant decrease in concentration during the pubertal growth spurt has also been demonstrated coincident with a rise in insulin level^.^^^"' The latter observation suggests that decreased IGF BP-I synthesis during puberty is related to the enhanced production of insulin. A non-hGH dependent protein, IGF BP-4, (25 kD) whose physiological role is as yet uncertain, is also present in serum. This binding protein and others of molecular mass in the range 25-42 kD7' require further detailed studies before a specific physiological role can be attributed to them. Reagents are available for the measurement of the GH-dependent IGF BP-3. A novel approach to its measurement was devised by Martin and B a~t e r~~ using antibodies raised to the acid-stable glycosylated binding proteins dissociated from 1GF BP-3 complex.
There are two different models for the structure source of IGF-I and the binding proteins. The half-life of IGF BP-3 is approximately 15 h whereas unbound IGF-I has a half-life of 10 m i r~.~' In animal models the synthesis of IGF-Ibinding proteins is modulated by the presence of growth hormone, thyroxine and cortisol.80.81 DNA sequences are known for all three major IGF binding proteins found in normal serum.82-84 The amino-acid composition reveals a high content of cysteine residues in each binding protein, suggesting a significant degree of disulphide bridge conservation between the three. s4
. A schematic structure of the hGH dependent IGF BP-complex present in human serum (a). The Mr on SDS-PAGE of the two acid stable subunits either non-reduced or reduced, is illustrated in (b). The dvference in
Receptors for IGF-I
Hormones elicit their biological responses at cellular level when specific receptors are present. Figure 4 illustrates two specific receptors for IGF-I and 11 that are found in a variety of tissues including placental membrane^,^' myoblastssh and fibroblast^.^^ The 130 kD receptor (type R1) has a binding site with a high affinity for IGF-I and has a structure that is similar to that of the insulin receptor. On the other hand, the 260 kD receptor (type R2) has a high affinity for IGF-I1 and the presence of insulin increases the number of these receptors on the cell surface. Two immunologically distinct binding sites on the 130 kD receptor have been identified, one selectively binding IGF-I and a second which binds IGF-II.88 The full significance of this is not understood. It is not known whether the free (non-protein bound) fraction or a complex of IGF-1/11 bound to one of the specific binding proteins is the trigger for the intracellular events that follow receptor binding and are depicted in Fig. 4 . There is a progressive decline in the binding affinity of IGF-I for fibroblast receptors as the age of the fibroblast donor increases.s7 This observation suggests that the binding of growth factors t o receptors is dependent not only on their adequate synthesis but also on receptor number, avidity, and age. The effect of age on receptor binding of IGF-I in other tissues is well illustrated by Hill and colleaguessy in a study of IGF binding to receptors in pre-and post-natal rat cartilage. The discovery of a paracrine or autocrine secretion of IGF-I in many tissues38 has posed the question of the biological importance of peripheral levels of IGF-I compared with local tissue production. For example, modulation of steroid synthesis induced by trophic hormone-binding to specific ACTH or LH receptors in the adrenal or gonafi, respectively, has been attributed to local synergis!ic effects of I G F -I .~~ 
Tissue receptors for IGF-I and IGF-If, illuslrating the biological response induced when the growth
CLINICAL RELEVANCE OF LGH, IGF-I AND I1
hGH
The radioimmunoassay of hGH in serum has been available since the early 1960s. Since then it has been widely applied to the differential diagnosis of growth defects. The plethora of reported dynamic tests (at least 25) for the diagnosis of h G H deficiency or syndromes of excess hGH release support the view that none of the protocols adopted is entirely satisfactory.
More recently, urinary hGH measurements have been advocated as a non-invasive test." A number of well-tried tests have, however, been identified92 and with notable exceptions they are cost effective. Table 4 outlines those tests in current use which, when conducted according to the precise protocols described by the authors, are helpful in the diagnosis of hGH deficiency in different age groups. Figure 5 illustrates the relative cost of these tests.Y3
IGF-I
The application of immunoassays for IGF-I has led to the view that a basal IGF-I measurement may be all that is required for the diagnosis of hGH deficiency or excess. Earlier expectations of an IGF-I concentration as a clearcut differential diagnostic tool have not, however, been borne out. An overlap is demonstrable between IGF-I concentrations in the serum from patients that have either an adequate or inadequate hGH release during hGH provocation test^.'^^^^ This finding is the same whether a bioassayyh or an RIA is used for IGF-I measurements.
The discriminatory power of serum IGF-I measurements t o diagnose children with growth hormone deficiency may be improved when age or sexual maturation is taken into consideration." In the normal population, a sex difference in serum IGF-I concentrations is demonstrable, with higher IGF-I levels in girls than boys as adolescence intervene^.^"^^^ The importance of sex steroid concentration in the interpretation of serum IGF-I levels is illustrated by changes induced by the administration of either androgen or oestrogen.'"'~'"' A rise in IGF-I concentration after androgen or oestrogen therapy does not mean that sex steroids are the primary agents that cause the rise during the early stage of normal pubertal development. It may be related to enhanced GH-releasing hormone synthesis with a subsequent rise in and an increased pulsatility of hGH.Im A further complication when interpreting serum IGF-I levels during puberty is the increase in insulin levels as puberty interveneslo3 that stimulates IGF-I synthesis.'" Low calorie and reduced total energy intake are major causes of a decreased synthesis of IGF-I.'05The quality of calorie intake also changes IGF-I concentrations,'" an improved protein and essential amino acid content of the 
IGF-I1
The study of IGF-11 in serum of patients with growth defects has been hampered by a lack of good quality reagents. An early report suggested little difference in IGF-I1 concentrations between hypopituitary and normal children but raised levels in acromegaly.'2" Others, however, suggest that there is a difference in IGF-I1 concentrations between reference populations and hGH deficient patients, and that when IGF-I1 concentrations are combined with IGF-I concentrations diagnostic accuracy is improved.'21 Hardouin et al. 75 observed that IGF-I1 appears to bind IGF BP-3 with a higher affinity than IGF-I and because IGF-1 is low in patients with hGH deficiency, IGF-I1 may be preferentially bound. Thus, the combined measurement of IGF-I and I1 is likely to enhance the differential diagnosis of G H deficiency from other causes of poor growth.I2'
Treatment with hGH
Bioengineered hGH is now available in unlimited supply for the treatment of GH deficiency. The assay of serum IGF-I concentrations during hGH therapy should be a useful predictor of potential height in children because a positive correlation between an increase in height with age and basal IGF-I concentrations is demonstrable in normal populations.'22 This has not been substantiated in a study of children with retarded growth, which failed to show a positive correlation between IGF-I concentrations and growth rate following hGH treatment.12' Further, some children showed a good growth response to hGH, but a negligible rise in serum IGF-1 levels. The situation is further complicated because hGH or IGF-I receptor defects may be present in the heterogeneous population of patients under treatment with hCH.
Prior to the production of genetically engineered hGH, human pituitary extracts were the only suitable source of hGH for treatment. These preparations were shown to be biologically active, increasing calcium and hydroxyproline excretion, enhancing fatty acid synthesis, nitrogen retention and growth velocity.124.12s The preparations were withdrawn for treatment in 1985 because of the potential risk of contamination with slow virus.12h It is evident, therefore, that many of the earlier investigations on the therapeutic and biological effects of h G H require additional confirmation using bioengineered preparations. Studies in a recent review confirm the biological potency and benefits of these preparations. 127 There remains, however, much to be discovered about the best treatment schedules and, at a biochemical level, about the effect of rhGH treatment on IGF-I and binding protein synthesis. Future studies will require the clinical and biochemical investigation of conditions such as primary or secondary malnutrition and other diseases associated with restricted growth before and during the therapeutic use of hGH. 
